Overview

* Pyxis Oncology ( PYXS ) reports Q3 net loss of $22 mln, consistent with prior year

* Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025

* Expected cash runway through data milestones into second half of 2026

Outlook

* Pyxis Oncology ( PYXS ) expects preliminary data from MICVO studies in 4Q25

* Company anticipates cash runway into second half of 2026

* Pyxis Oncology ( PYXS ) to announce next steps in MICVO development with data update

Result Drivers

* G&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees

* TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.35

Q3 Net -$22 mln

Income

Q3 Basic -$0.35

EPS

Q3 -$23.46

Income mln

from

Operatio

ns

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)